40054 Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

EDN data entry staff at state and local health 

departments.

US Tuberculosis Follow-up Worksheet for 

Newly-Arrived Persons with Overseas Tuberculosis Classifications.

1,548 3 30/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–15793 Filed 7–23–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Health Statistics 

(NCHS), ICD–10 Coordination and 

Maintenance (C&M) Committee 

Meeting 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: The CDC, National Center for 

Health Statistics (NCHS), Classifications 

and Public Health Data Standards Staff, 

announces the following meeting of the 

ICD–10 Coordination and Maintenance 

(C&M) Committee meeting. This 

meeting is open to the public, limited 

only by audio. Online Registration is not 

required. 

DATES: The meeting will be held on 

September 14, 2021, from 9:00 a.m. to 

5:00 p.m., EDT, and September 15, 

2021, from 9:00 a.m. to 5:00 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Information will be provided on each of 

our respective web pages when it 

becomes available. For CDC/NCHS 

https://www.cdc.gov/nchs/icd/icd10cm_

maintenance.htm. For CMS https://

www.cms.gov/Medicare/Coding/ 

ICD9ProviderDiagnosticCodes/meetings. 

FOR FURTHER INFORMATION CONTACT: 

Traci Ramirez, Medical Systems 

Specialist, CDC, 3311 Toledo Road, 

Hyattsville, Maryland 20782; 

Telephone: (301) 458–4454; Email: 

TRamirez@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The ICD–10 Coordination 

and Maintenance (C&M) Committee is a 

public forum for the presentation of 

proposed modifications to the 

International Classification of Diseases, 

Tenth Revision, Clinical Modification 

and ICD–10 Procedure Coding System. 

Matters To Be Considered: The 

tentative agenda will include 

discussions on ICD–10–CM and ICD– 

10–PCS topics listed below. Agenda 

items are subject to change as priorities 

dictate. 

Please refer to the posted agenda for 

updates one month prior to the meeting. 

ICD–10–PCS Topics 

1. Administration of fostamatinib(1), (2) 

2. Administration of betibeglogene 

autotemcel (beti-cel)(1) 

3. Administration of RBX2660(1) 

4. Pressure-controlled Intermittent 

Coronary Sinus Occlusion 

5. Measurement of Exhaled Nitric Oxide 

(FeNo) 

6. Histotripsy of Liver 

7. Replacement of Meniscus with 

Synthetic Substitute (1) 

8. Section X Updates 

9. Addenda and Key Updates 

(1) Applicant intends to submit a New 

Technology Add-on Payment (NTAP) 

application for FY 2023. 

(2) Request is for an April 1, 2022 

implementation date. 

Presentations for procedure code 

requests are conducted by both the 

requestor and CMS during the 

Coordination & Maintenance Committee 

meeting. Discussion from the requestor 

generally focuses on the clinical issues 

for the procedure or technology, 

followed by the proposed coding 

options from a CMS analyst. Topics 

presented may also include requests for 

new procedure codes that relate to a 

new technology add-on payment 

(NTAP) policy request. 

CMS is continuing to modify the 

approach for presenting the new 

technology add-on payment (NTAP) 

related ICD–10–PCS procedure code 

requests that involve the administration 

of a therapeutic agent. Consistent with 

the requirements of section 

1886(d)(5)(K)(iii) of the Social Security 

Act, applicants submitted requests to 

create a unique procedure code to 

describe the administration of a 

therapeutic agent, such as the option to 

create a new code in Section X within 

the ICD–10–PCS procedure code 

classification. CMS will initially only 

display those meeting materials 

associated with the NTAP related ICD– 

10–PCS procedure code requests that 

involve the administration of a 

therapeutic agent on the CMS website in 

early August 2021 at: https://

www.cms.gov/Medicare/Coding/ICD10/ 

C-and-M-Meeting-Materials. 

The three NTAP related ICD–10–PCS 

procedure code requests that involve the 

administration of a therapeutic agent 

are: 

1. Administration of fostamatinib 

2. Administration of betibeglogene 

autotemcel (beti-cel) 

3. Administration of RBX2660 

These topics will not be presented 

during the September 14–15, 2021 

meeting. CMS will solicit public 

comments regarding any clinical 

questions or coding options included for 

these three procedure code topics in 

advance of the meeting continuing 

through the end of the public comment 

period. The deadline to submit 

comments for topics being considered 

for April 1, 2022 implementation is 

October 15, 2021 and the deadline to 

submit comments for topics being 

considered for an October 1, 2022 

implementation is November 15, 2021. 

Members of the public should send any 

questions or comments to the CMS 

mailbox at: ICDProcedureCodeRequest@

cms.hhs.gov by the designated deadline 

dates mentioned above. 

CMS intends to post a question and 

answer document in advance of the 

meeting to address any clinical or 

coding questions that members of the 

public may have submitted. Following 

the conclusion of the meeting, CMS will 

post an updated question and answer 

document to address any additional 

clinical or coding questions that 

members of the public may have 

submitted during the meeting that CMS 

was not able to address or that were 

submitted after the meeting. 

The NTAP related ICD–10–PCS 

procedure code requests that do not 

involve the administration of a 

therapeutic agent and all non-NTAP 

related procedure code requests will 

continue to be presented during the 

virtual meeting on September 14, 2021 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices 40055 

consistent with the standard meeting 

process. 

CMS will make all meeting materials 

and related documents available at: 

https://www.cms.gov/Medicare/Coding/ 

ICD10/C-and-M-Meeting-Materials. Any 

inquiries related to the procedure code 

topics scheduled for the September 14, 

2021 ICD–10 Coordination and 

Maintenance Committee meeting that 

are under consideration for April 1, 

2022 or October 1, 2022 implementation 

should be sent to the CMS mailbox at: 

ICDProcedureCodeRequest@

cms.hhs.gov. 

ICD–10–CM Topics 

1. Apnea of Newborn and Related Issues 

2. Atrial Septal Defect 

3. Craniosynostosis 

4. Dementia 

5. Encounter for follow-up examination 

after completed treatment for 

malignant neoplasm 

6. Endometriosis 

7. Intracranial Injury with Unknown 

LOC 

8. Long-term (current) drug therapy 

9. Primary Blast Injury 

10. Problems Related to Upbringing 

11. Short Stature Due to Endocrine 

Disorder 

12. Addenda 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–15801 Filed 7–23–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–1046; Docket No. CDC–2021– 

0074] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled National Breast and Cervical 

Cancer Early Detection Program 

(NBCCEDP) Monitoring Activities. 

Proposed study is designed to collect 

information about implementation, 

including delivery of screening and 

follow-up clinical services, and 

outcomes of the NBCCEDP. 

DATES: CDC must receive written 

comments on or before September 24, 

2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0074 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP) 

Monitoring Activities—(OMB Control 

No. 0920–1046, Exp. 11/30/2021)— 

Revision—National Center for Chronic 

Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

CDC is requesting a Revision of the 

information collection with the OMB 

Control Number 0920–1046, titled 

‘‘National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP) 

Monitoring Activities.’’ In the previous 

OMB approval period, information 

collection consisted of an annual 

NBCCEDP survey and clinic-level data 

collection. In the next OMB approval 

period, information collection will 

consist of a revised NBCCEDP survey, 

revised clinic-level data collection, new 

quarterly program update, new service 

delivery projection worksheet, and the 

addition of previously approved 

minimum data elements (MDEs; OMB 

Control No. 0920–0571, Exp. 11/30/ 

2021) to increase efficiency. The 

number of respondents will remain the 

same and the total estimated annualized 

burden will increase from 683 to 1,216. 

Breast and cervical cancers are 

prevalent among U.S. women. In 2017, 

the U.S. experienced 250,520 new cases 

and 42,000 deaths as a result of breast 


jbell on DSKJLSW7X2PROD with NOTICES